Join Kathleen Horst, MD and Melinda Telli, MD as they present their multidisciplinary expertise on a range of cases pertaining to locally advanced disease breast cancer.

Breast cancer continues to be the second leading cause of cancer death in women, exceeded only by lung cancer. Due to the complexity of care involved, it is very important for the multidisciplinary cancer team (consisting of a surgeon, pathologist, radiation oncologist, medical oncologist) to coordinate not only with each other but also with primary care physicians and specialist care teams to implement and deliver comprehensive, efficient, and patient-centered care.   Selecting the most efficient systemic therapy approach for locally advanced disease is based not only on patient characteristics (comorbidities), tumor characteristics (size, nodal status) but also heavily on tumor biomarkers (ER, PR, and HER2). Therefore, the clinicians need to be aware of the importance of accurate assessment of the status of tumor biomarkers.  With respect to neoadjuvant/adjuvant systemic therapy, the results of recent trials have led to approval of new agents and new therapeutic strategies.  The clinicians need to stay up-to-date with the continuously evolving standard-of-care.